Delcath Systems (NASDAQ: DCTH) — Perfil da empresa, notícias e dados financeiros
Delcath Systems specializes in precision oncology targeting liver cancer treatments.
Delcath Systems
Delcath Systems (NASDAQ:DCTH) specializes in precision oncology, focusing on the development and commercialization of innovative treatments for primary and metastatic cancers of the liver. The company is known for its proprietary percutaneous hepatic perfusion (PHP) technology, aimed at isolating the liver's blood flow and delivering high doses of anti-cancer drugs to the liver while minimizing systemic exposure. This unique approach allows for targeted treatment of liver cancers, potentially improving patient outcomes and reducing side effects compared to traditional systemic chemotherapy. Delcath Systems is committed to advancing its research and development initiatives to address the unmet needs in liver cancer treatment, striving to improve survival rates and the quality of life for patients facing this challenging disease.
Resumo
Operações
Produtos e/ou serviços de Delcath Systems
- Chemosaturation Therapy: A surgical procedure delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure.
- CHEMOSAT: A proprietary system designed for the administration of chemosaturation therapy with melphalan.
- Melphalan/HDS: A hepatic delivery system for high-dose melphalan chemotherapy targeting liver cancers.
- Clinical Trials: Ongoing research studies to evaluate the effectiveness and safety of chemosaturation therapy in treating patients with liver cancers.
- Educational Programs: Initiatives to provide training and resources for healthcare professionals on the use of their liver-directed therapies.
- Partnerships and Collaborations: Strategic alliances with medical institutions and companies to advance research and increase access to their treatments.
equipe executiva do Delcath Systems
- Gerard J. MichelCEO & Director
- Martha S. RookChief Operating Officer
- Vojislav VukovicChief Medical Officer
- Sandra PennellChief Financial Officer
- David HoffmanGeneral Counsel, Corporate Secretary & Chief Compliance Officer
- Kevin MuirChief Commercial Officer
- Michael BrunnerSenior Vice President of Interventional Oncology
Últimas notícias sobre a Delcath Systems
Principais indicadores financeiros
Resultados divulgados pela Delcath Systems, em USD.
- Cap. de mercado
- 511,8 mi
- Receita (TTM)
- 95,4 mi
- P/L
- 1475.0
- LPA (diluído, TTM)
- 0.0
- Dividend yield
- —
- Margem de lucro
- 0.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 85,2 mi | 660 mil | 2,7 mi | |
| 37,2 mi | -12,4 mi | -26,4 mi | |
| 2,1 mi | -38,2 mi | -47,7 mi | |
| 2,7 mi | -33,9 mi | -36,5 mi |